09 | The Wait Is Optional - with Frank Nogueira

Francisco (Frank) Nogueira is CEO of Accumulus Technologies, where he leads the continued evolution and global adoption of the Accumulus Platform, helping transform regulatory collaboration to accelerate patient access to medicines. Prior to leading Accumulus Technologies, he served as Chief Executive Officer of the nonprofit Accumulus Synergy. He joined Accumulus in 2020 from Genentech, where he served as he served as Vice President of Regulatory Affairs at Roche. Accumulus Technologies is reimagining how life sciences organizations and national regulatory authorities work together to accelerate the drug development lifecycle, from drug discovery through global availability. Connecting industry to 75+ regulators around the globe, the Accumulus platform is a secure, purpose-built, SaaS platform that enables real-time collaboration and continuous data streaming - powering faster decisions, global alignment, and accelerated access to therapies for patients worldwide. 

The four connective tissues. Frank's frame for the last thirty years: the internet connected people, cloud connected enterprises, AI is connecting knowledge, and the next layer — the one still missing — is connected scientific evidence. That is what Accumulus is building. Frank says the community today is "data rich but information poor," and the volume of scientific evidence generated worldwide has become astonishing. Somebody has to move it, securely, in real time, without waiting three years per region.

The collision course. Large pharma is betting hard on AI, generating more data than ever, presenting it more ways than ever, with fewer people. Meanwhile some regulators are still receiving paper dossiers. Frank thinks the gap between leading and lagging regions doesn't just persist — it accelerates unless the digital infrastructure catches up. Gene and cell therapies mean smaller trials with smaller patient populations but larger information volumes per submission. His prediction for the next decade: regulator workload goes logarithmic.

Trust, reliance, and the manufacturing change problem. Frank spends real time on the reliance framework — one regulator leaning on another's review work. Manufacturing changes today can take three to five years to work through global regions, forcing companies to maintain parallel manufacturing lines or accept country-level shortages. What Accumulus is seeing on the platform: regulators watching those changes in real time, seeing the questions and answers as they happen, and concluding "they did everything we were going to do. They asked every question we were going to ask. In fact, they asked more. There's nothing for us to wait three years for."

Sovereignty is not the same as isolation. Frank is clear he isn't arguing for one mega-regulator. Each regulator maintains sovereignty and independence. But sovereignty is compatible with reliance, work-sharing, and specialization. Five countries in a region don't need five reviewers doing the same work in parallel — they can carve up the modules. Low-to-middle income regulators increasingly tell Frank they're relieved to be getting the same scientific package the FDA and EMA got, which increases trust in the system rather than eroding it.

The three camps. Frank divides industry into three groups. Camp one: the naysayers with a thousand reasons change won't work. Camp two: the curious middle, who Frank says used to be curious about whether it would work and are now curious about how to make it work in their own company. Camp three: the "let's go" people who see a thousand reasons this will be problematic and decide to figure it out anyway. Matt and Frank are both in camp three.

Technology isn't the bottleneck anymore. Frank's closing thesis, and Matt's too: this is no longer a technology problem. It's change management, vision, and incentives. The infrastructure exists. What determines the speed of adoption is how many companies and regulators move from wait-and-see to "let's go."

How Accumulus got here. The nonprofit Accumulus Synergy was formally formed on July 13, 2020 out of quarterly regulator-industry conversations that had been running since 2019. The original scope was small — a handful of people and a large cloud provider. They ran a full year-long RFI/RFP with the three main cloud providers. The winner worked with them for three months and pulled out, saying it was too complex and outside their core business. That refusal is what forced Accumulus to become a technology company itself.

Nonprofit skepticism and the spinout. The nonprofit ran into skepticism from two directions. Inside the U.S., people said big pharma funds it, so how nonprofit is it really. Outside the U.S., the concept didn't translate. Regulators told Frank they didn't want to work one way for large pharma, another for mid-size, another for small biotech. Building a growth-hungry SaaS platform inside a nonprofit shell got harder every quarter. On August 4, 2025, Accumulus Synergy spun out Accumulus Technologies as a commercial entity — turning one year old as a commercial company right around the time this was recorded.

Public benefit corporation: a side quest worth taking. Matt asks if Frank considered a PBC for the spinout. He did, but sees PBCs today as more branding than structural — many are still fully driven by revenue and shareholder value. Matt pushes back with his own PBC pharma experience: the incentive is real, but no publicly endorsed measurement standard exists for pharma-specific impact. B Corp doesn't quite fit. Matt's take: there's opportunity for existing PBCs to define and publicize the standard themselves as a differentiator.

Frank on the real barrier: "Technology is absolutely no longer a factor. It is mostly change management."

Frank on the four-layer progression: "The internet connected people... cloud connected enterprises... AI is connecting knowledge... our next step is to connect scientific evidence."

Frank on where the industry actually sits: "The community in general is data rich but information poor."

Frank on reliance in the wild: "They did everything we were going to do. They asked every question we were going to ask. In fact, they asked more. There's nothing for us to wait three years for."

Frank on the paper-dossier gap: "You have regulators who are still receiving paper dossiers, and you can see why those two are on a collision course."

Frank on the wait-and-see camp: "Change is even more uncomfortable than the parts of my job I don't like."

Frank on the closing frame: "We no longer believe that every country is an island."

Regulatory strategy and operations leaders inside pharma, health authority technologists thinking about digital submissions and reliance pathways, RIM teams, and anyone building or buying tech that has to interoperate across sovereign regulators. Also for anyone who has looked at a three-to-five-year approval tail and quietly wondered why the industry treats it as physics rather than a decision.

Accumulus Technologies (commercial spinout)

Francisco Nogueira on LinkedIn

Accumulus Synergy spins out Accumulus Technologies (Aug 4, 2025)

Nogueira appointed CEO of Accumulus Synergy (May 13, 2021)

Operations Utopia - Where Regops, Innovation, Technology, and Execution Meet.

Disclaimer: This podcast reflects only the opinion of the podcaster and guests and does not reflect those of their organizations, system vendors, or service provider

Original show theme "Little Sammy" by Matt Neal